Literature DB >> 17336566

Association between gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia: analysis using pharmacovigilance tools.

Manfred Hauben1, Sebastian Horn, Lester Reich, Muhammad Younus.   

Abstract

OBJECTIVE: Recent epidemiological studies identifying an association between some classes of gastric acid suppressants and Clostridium difficile colitis and community-acquired pneumonia prompted our analysis. Our objective was to retrospectively apply data mining algorithms (DMAs) to the Food and Drug Administration (FDA) drug safety database to see if they might have directed/redirected attention to the reported association of gastric acid suppressive drugs with C. difficile colitis and community-acquired pneumonia, prior to the published epidemiological findings that supported the association.
DESIGN: Two statistical DMAs, proportional reporting ratios (PRRs) and multi-item gamma Poisson shrinker (MGPS), were applied to a spontaneous reporting system (SRS) database to identify signals of disproportionate reporting (SDRs).
RESULTS: SDRs related to community-acquired pneumonia were observed for two proton pump inhibitors (lansoprazole and omeprazole), two H2 antagonists (famotidine and roxatidine), and one antacid (magnesium silicate hydroxide). For C. difficile colitis, an SDR was generated for one proton pump inhibitor (lansoprazole).
CONCLUSIONS: Although our analysis suggests that there may be an association between the SDRs using SRS data and the epidemiological findings, these results may not have alerted public health professionals in advance of published studies to an association between proton pump inhibitors/gastric acid suppressants and C. difficile colitis or community-acquired pneumonia. However, the analysis reveals the potential utility of DMAs to direct attention to more subtle indirect drug adverse effects in SRS databases that as yet are often identified from epidemiological investigations.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17336566     DOI: 10.1016/j.ijid.2006.11.004

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  8 in total

Review 1.  Safety of the long-term use of proton pump inhibitors.

Authors:  Alan B R Thomson; Michel D Sauve; Narmin Kassam; Holly Kamitakahara
Journal:  World J Gastroenterol       Date:  2010-05-21       Impact factor: 5.742

2.  Clostridium difficile: the emerging epidemic.

Authors:  Nasia Safdar
Journal:  Mayo Clin Proc       Date:  2012-11       Impact factor: 7.616

Review 3.  Quality improvement in gastroenterology clinical practice.

Authors:  Rakhi Kheraj; Sumeet K Tewani; Gyanprakash Ketwaroo; Daniel A Leffler
Journal:  Clin Gastroenterol Hepatol       Date:  2012-08-16       Impact factor: 11.382

Review 4.  Do proton pump inhibitors protect against cancer progression in GERD?

Authors:  Tomoharu Miyashita; Furhawn A Shah; John W Harmon; Guy P Marti; Daisuke Matsui; Koichi Okamoto; Isamu Makino; Hironori Hayashi; Katsunobu Oyama; Hisatoshi Nakagawara; Hidehiro Tajima; Hideto Fujita; Hiroyuki Takamura; Manabu Murakami; Itasu Ninomiya; Hirohisa Kitagawa; Sachio Fushida; Takashi Fujimura; Tetsuo Ohta
Journal:  Surg Today       Date:  2012-10-31       Impact factor: 2.549

5.  Association Patterns in Open Data to Explore Ciprofloxacin Adverse Events.

Authors:  P Yildirim
Journal:  Appl Clin Inform       Date:  2015-12-16       Impact factor: 2.342

Review 6.  Long-term proton pump inhibitor use and gastrointestinal cancer.

Authors:  David Y Graham; Robert M Genta
Journal:  Curr Gastroenterol Rep       Date:  2008-12

7.  Risk of bronchospasm and coronary arteriospasm with sugammadex use: a post marketing analysis.

Authors:  Pushkar Aggarwal
Journal:  Ther Adv Drug Saf       Date:  2019-08-18

8.  Colonization of Toxigenic Clostridium difficile Among Intensive Care Unit Patients: A Multi-Centre Cross-Sectional Study.

Authors:  Hongfei Mi; Rong Bao; Yao Xiao; Yangwen Cui; Wei Sun; Yan Shen; Qingfeng Shi; Xiang Chen; Jiabing Lin; Bijie Hu; Xiaodong Gao
Journal:  Front Cell Infect Microbiol       Date:  2020-01-30       Impact factor: 5.293

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.